Animal

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

Retrieved on: 
Monday, April 22, 2024
Combination, Cancer, FOLFIRINOX, Pancreatic cancer, Poster, Animal, Irinotecan, Cell, PDAC, Real-time, Therapy, Patient, Gene, Society, Neoplasm, Oncolytic adenovirus, Pharmaceutical industry

ROCKVILLE, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of preclinical data demonstrating enhanced anti-tumor effects in human pancreatic cancer xenograft-bearing mice treated with lead product candidate VCN-01 and liposomal irinotecan. These data support the potential synergy of VCN-01 and first-line pancreatic cancer chemotherapy regimens, and will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.

Key Points: 
  • These data support the potential synergy of VCN-01 and first-line pancreatic cancer chemotherapy regimens, and will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.
  • “We look forward to leveraging these findings and evaluating the combination of VCN-01 with additional first-line pancreatic cancer chemotherapy regimens, including NALIRIFOX and FOLFIRINOX.
  • In vivo: Synergy of VCN-01 plus liposomal irinotecan was observed in animals bearing subcutaneous human pancreatic tumors.
  • Combination therapy with VCN-01 + liposomal irinotecan at either dose displayed significantly reduced tumor growth compared to each treatment alone.

Hospice Choices: VITAS® Healthcare Opens in Alabama, Expands in Florida Panhandle

Retrieved on: 
Wednesday, April 17, 2024
Music therapy, Florida Panhandle, Android, Nursing, Hospice, VITAS, Animal, Health care, VITAS Healthcare, Live, TPN, Family, Patient, Caregiver, Music, Specialization, Complex, Respiratory therapist, IOS

TALLAHASSEE, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Hospice patients and their families in the Florida Panhandle and areas in Southern Alabama can now access quality end-of-life services with VITAS Healthcare. Starting today, the nation’s largest and leading provider of end-of-life care begins accepting referrals and admitting seriously ill patients throughout Tallahassee in Florida and Daphne-Mobile and Dothan in Alabama.

Key Points: 
  • TALLAHASSEE, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Hospice patients and their families in the Florida Panhandle and areas in Southern Alabama can now access quality end-of-life services with VITAS Healthcare.
  • When patients in the Panhandle region need care beyond what can be managed at home, VITAS offers inpatient hospice care.
  • In March 2024, VITAS entered into an agreement to acquire all hospice operations and an assisted living facility from Covenant Care.
  • Healthcare professionals can make seamless and secure one-touch referrals through the VITAS Healthcare mobile app .

Rogers $1M Season of Canada’s Got Talent: Top Performances from Tonight’s Episode on Citytv

Retrieved on: 
Wednesday, April 17, 2024
EVE, Labrinth, SOON, Disability, SAM, Animal, AB, CGT, NOAH, QC, Cat, CIBC, Omnichord, Lilly, Maple, Nightclub

82-year-old SOON KEUN KWON (Mississauga, ON) received a standing ovation after wow’ing the crowd with his incredible drum playing.

Key Points: 
  • 82-year-old SOON KEUN KWON (Mississauga, ON) received a standing ovation after wow’ing the crowd with his incredible drum playing.
  • Every Golden Buzzer recipient will receive $25,000 (totalling $150,000), courtesy of CIBC, to help realize their ambitions.
  • Together with Canada’s Got Talent, Rogers is committed to investing in premium original Canadian content while fostering homegrown talent.
  • Last year, Rogers contributed approximately $950M to Canadian content and produced over 12,700 hours of unique Canadian programming.

Jaya Biosciences Presents Updated Preclinical Data in Alzheimer’s Disease at the 45th SIMD Annual Meeting

Retrieved on: 
Tuesday, April 16, 2024
GUSB, Society, PPT1, IDUA, Haploinsufficiency, Gene dosage, Central Waqf Council, Animal, GALC, Research, AAV, IND, CNS, Disease, Science, NAGLU, Patient, DSM-IV codes, SIMD, Toxicology, Annual general meeting, Plaque, SAN, Gene, APP, Antibiotics

During a podium presentation, Jaya Biosciences’ scientific founder and science advisory board chair, Professor Mark Sands, reported on recently updated human genetic analyses suggesting that heterozygous loss-of-function mutations in lysosomal enzyme genes are enriched in Alzheimer’s disease (AD) patients.

Key Points: 
  • During a podium presentation, Jaya Biosciences’ scientific founder and science advisory board chair, Professor Mark Sands, reported on recently updated human genetic analyses suggesting that heterozygous loss-of-function mutations in lysosomal enzyme genes are enriched in Alzheimer’s disease (AD) patients.
  • This new analysis generated from a much larger whole genome sequence database confirmed their previous human genetic findings from a smaller whole exome database.
  • “The updated human genetic data confirmed that heterozygous deleterious mutations in a subset of lysosomal genes are enriched in patients with Alzheimer’s disease,” said Prof. Mark Sands.
  • For more information about the 45th SIMD Annual Meeting, please go to SIMD2024 Meeting .

GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING

Retrieved on: 
Tuesday, April 16, 2024
Pain, Electrode, SCS, Epidural space, Neurological disorder, Animal, Diabetes, CGM, Electricity, Doctor of Philosophy, Blood, PDN, Patient, Spinal cord stimulator, Spinal cord, Glucose, Hypoesthesia, Quality of life, Medical device

Rutherford, NJ, April 16, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural space. A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).

Key Points: 
  • A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).
  • Combining SCS and continuous glucose monitoring (CGM) could provide several possible advantages, such as simplifying device management for those patients.
  • This is the second application of Glucotrack’s technology for implantable continuous glucose monitoring, in addition to its development of a long-term Continuous Blood Glucose Monitoring (CBGM) system.
  • The results demonstrated the Glucotrack epidural glucose values closely tracked both the blood glucose and subcutaneous CGM values.

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Retrieved on: 
Tuesday, April 16, 2024
Osteoarthritis, Economics, TELO, Hematology, Animal, Cleveland Clinic, Research, IND, Weakness, DRS, Medicine, Press club, Ageing, Longevity, Pharmaceutical industry

WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on Telomir-1 as a potential treatment for age-related conditions, today recapped its presentation of compelling pre-clinical data on Telomir-1 at a high-profile event hosted at the National Press Club in Washington, D.C., on April 15, 2024.

Key Points: 
  • As part of its commitment to transparency and openness in sharing its research data, during the event, Drs.
  • Chapman and Roizen presented company data that showed the effect of Telomir-1, a novel molecule designed to modulate telomerase activity and elongate telomeres.
  • The data show that telomeres lengthened in vitro in human cells and telomerase activity increased by 40%.
  • “Our National Press Club event was our first opportunity to share on a national stage Telomir-1’s potential to combat the diseases of aging,” stated Dr. Chapman.

Zoetis (ZTS) Drops on Report that Arthritis Drugs May Sicken Pets – Hagens Berman

Retrieved on: 
Monday, April 15, 2024
Person, ZTS, Animal, Hagens Berman, WSJ, Pet, Pharmaceutical industry

12, 2024, the price of Zoetis shares fell $12.75, or nearly 8%, after the WSJ published “What Killed Their Pets?

Key Points: 
  • 12, 2024, the price of Zoetis shares fell $12.75, or nearly 8%, after the WSJ published “What Killed Their Pets?
  • Owners Blame Meds, but Vets Aren’t Sure.”
    The WSJ’s article focuses on Zoetis’ Librela and Solensia, therapies intended to relieve painful canine and feline osteoarthritis, respectively.
  • But, the WSJ report may have brought Zoetis’ peak sales goal into question due to reports that pet owners who have blamed the drugs for sickening their animals, some of whom have died.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami

Retrieved on: 
Monday, April 15, 2024
FDA, Fear, Safety, Research, Animal, Levetiracetam, Epilepsy, Seizure, UCB, Liver, Patient, MES, Toxicity, CBDS, Medication, PTZ, 1A2, Dietary supplement

LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and predictable PK parameters.

Key Points: 
  • LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and predictable PK parameters.
  • CBDS maintains improved oral formulation capabilities vs cannabidiol, including tablet and water-based solutions.
  • This data was presented at the prestigious ETDD XVII conference in Miami on June 2nd, 2023, and was well received by the expert audience.
  • Following their presentation at ETDD XVII, London Research & Pharmaceuticals accepted a podium presentation invitation from Dr. Meir Bialer at the EILAT XVII held in Madrid, May 2024.

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Retrieved on: 
Monday, April 15, 2024
FDA, Cancer, Safety, Food, Glioblastoma, Animal, Survival, Breast, RNA, IND, Transcoding, Therapy, Senior, Patient, Investigational New Drug, Pharmaceutical industry

FDA’s clearance of our IND application represents a significant milestone for our company,” commented Sue Duggan, Senior Vice President, Operations, at TransCode.

Key Points: 
  • FDA’s clearance of our IND application represents a significant milestone for our company,” commented Sue Duggan, Senior Vice President, Operations, at TransCode.
  • The Phase 1/2 clinical trial is designed to generate critical data to support evaluation of the safety of TTX-MC138 and may provide early evidence of its clinical activity in patients with metastatic disease.”
    The Phase 1/2 clinical trial includes an initial dose-escalation phase followed by a dose-expansion phase.
  • The dose-escalation portion of the trial is designed to include patients with a variety of metastatic solid cancers.
  • In the dose-expansion phase, certain tumor types will be evaluated based on preliminary results from the dose-escalation phase.

Zoetis (ZTS) Drops on Report that Arthritis Drugs May Sicken Pets – Hagens Berman

Retrieved on: 
Saturday, April 13, 2024
Person, Animal, ZTS, Pet, Hagens Berman, WSJ, SAN, Knowledge

12, 2024, the price of Zoetis shares fell $12.75, or nearly 8%, after the WSJ published “What Killed Their Pets?

Key Points: 
  • 12, 2024, the price of Zoetis shares fell $12.75, or nearly 8%, after the WSJ published “What Killed Their Pets?
  • Owners Blame Meds, but Vets Aren’t Sure.”
    The WSJ’s article focuses on Zoetis’ Librela and Solensia, therapies intended to relieve painful canine and feline osteoarthritis, respectively.
  • But, the WSJ report may have brought Zoetis’ peak sales goal into question due to reports that pet owners who have blamed the drugs for sickening their animals, some of whom have died.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.